•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.CSU Digital Launches U.S. Market Expansion at New York Executive Summit
4 P&C Insurers Stocks Poised to Weather 2026 Hurricane Season
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
Vertus Group Expands Operations into Mexico with Latest Acquisition
CORA Group Acquires Finastra's Phoenix Core System, Malauzai Digital Banking and Fusion Analytics Businesses
Constellation Software Inc. Confirms Closing of DerbySoft Acquisition Through Juniper Group
Constellation Software Inc. (CSU:CA) Shareholder/Analyst Call Transcript
Constellation Software Inc. Announces Results of Voting for Directors at Annual General Shareholders' Meeting
Constellation Software Inc. Announces Results for the First Quarter Ended March 31, 2026 and Declares Quarterly Dividend
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial
Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Constellation Software Inc. Announces Conference Call to Discuss First Quarter Results
Constellation Software's Vela Operating Group Enters into Agreement to acquire a majority interest in Derbysoft Holdings Limited
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Constellation Software Inc. (TSE:CSU) Given Average Rating of “Moderate Buy” by Analysts
Constellation Software Inc. Announces Mark Leonard's Decision to not Stand for Re-Election to Board of Directors
Constellation Software Inc. (CSU:CA) Q4 2025 Earnings Call Transcript
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026